|
|
Volumn 53, Issue 12, 2004, Pages 1153-1158
|
|
Cancer Immunotherapy 2004: Mainz, Germany, 6-7 May 2004
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIGEN;
CANCER VACCINE;
CD20 ANTIBODY;
DACARBAZINE;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
FC RECEPTOR;
HLA ANTIGEN CLASS 1;
IMMUNOLOGICAL ADJUVANT;
MONOCLONAL ANTIBODY;
PEPTIDE;
PERTUZUMAB;
REMOVAB;
T LYMPHOCYTE RECEPTOR;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ADOPTIVE IMMUNOTHERAPY;
ANTIGEN DETECTION;
ANTIGEN EXPRESSION;
CANCER GROWTH;
CANCER IMMUNOTHERAPY;
CELLULAR IMMUNITY;
CLINICAL TRIAL;
CONFERENCE PAPER;
DATA BASE;
DENDRITIC CELL;
HUMAN;
LYMPHOCYTE TRANSFER;
LYMPHOMA;
NATURAL KILLER CELL;
OVARY CANCER;
PRIORITY JOURNAL;
SIDE EFFECT;
T LYMPHOCYTE;
ADOPTIVE TRANSFER;
ANTIBODIES;
CANCER VACCINES;
CLINICAL TRIALS;
HUMANS;
IMMUNOTHERAPY;
KILLER CELLS, NATURAL;
NEOPLASMS;
T-LYMPHOCYTES;
|
|
EID: 8644243761
PISSN: 03407004
EISSN: None
Source Type: Journal
DOI: 10.1007/s00262-004-0580-2 Document Type: Conference Paper |
|
Times cited : (2)
|
|
References (0)
|
